Herceptin.net - Herceptin (trastuzumab) for treatment of HER2-positive breast cancer

skip to the content

News

Gelmon K. Part II: Milestones in personalised medicine—trastuzumab
Lancet Oncol 2008;9:698
More News

Early Breast Cancer

Herceptin delivers high cure rates for women with HER2-positive early breast cancer

Metastatic Breast Cancer

Herceptin extends the lives of women with

HER2-positive metastatic disease

More

Targeting HER2

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has a poor prognosis, with a high rate of recurrence and short disease-free intervals.

HER2 testing

Accurate HER2 testing is essential to correctly identify patients who may benefit from Herceptin.

Country Sites

Click here to get an overview of our country-specific websites.

Disclaimer: Herceptin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.herceptin.com. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
Privacy statement
Legal statement
Contact